These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Adoptive Cell Therapy Targeting Neoantigens: A Frontier for Cancer Research. Wang Z; Cao YJ Front Immunol; 2020; 11():176. PubMed ID: 32194541 [TBL] [Abstract][Full Text] [Related]
25. Low Mutation Burden in Ovarian Cancer May Limit the Utility of Neoantigen-Targeted Vaccines. Martin SD; Brown SD; Wick DA; Nielsen JS; Kroeger DR; Twumasi-Boateng K; Holt RA; Nelson BH PLoS One; 2016; 11(5):e0155189. PubMed ID: 27192170 [TBL] [Abstract][Full Text] [Related]
26. Dual-specific Chimeric Antigen Receptor T Cells and an Indirect Vaccine Eradicate a Variety of Large Solid Tumors in an Immunocompetent, Self-antigen Setting. Slaney CY; von Scheidt B; Davenport AJ; Beavis PA; Westwood JA; Mardiana S; Tscharke DC; Ellis S; Prince HM; Trapani JA; Johnstone RW; Smyth MJ; Teng MW; Ali A; Yu Z; Rosenberg SA; Restifo NP; Neeson P; Darcy PK; Kershaw MH Clin Cancer Res; 2017 May; 23(10):2478-2490. PubMed ID: 27965307 [No Abstract] [Full Text] [Related]
27. MHC class II restricted neoantigen: A promising target in tumor immunotherapy. Sun Z; Chen F; Meng F; Wei J; Liu B Cancer Lett; 2017 Apr; 392():17-25. PubMed ID: 28104443 [TBL] [Abstract][Full Text] [Related]
28. Functional analysis of peripheral and intratumoral neoantigen-specific TCRs identified in a patient with melanoma. Bräunlein E; Lupoli G; Füchsl F; Abualrous ET; de Andrade Krätzig N; Gosmann D; Wietbrock L; Lange S; Engleitner T; Lan H; Audehm S; Effenberger M; Boxberg M; Steiger K; Chang Y; Yu K; Atay C; Bassermann F; Weichert W; Busch DH; Rad R; Freund C; Antes I; Krackhardt AM J Immunother Cancer; 2021 Sep; 9(9):. PubMed ID: 34518289 [TBL] [Abstract][Full Text] [Related]
29. Adoptive T cell immunotherapy of human uveal melanoma targeting gp100. Sutmuller RP; Schurmans LR; van Duivenvoorde LM; Tine JA; van Der Voort EI; Toes RE; Melief CJ; Jager MJ; Offringa R J Immunol; 2000 Dec; 165(12):7308-15. PubMed ID: 11120866 [TBL] [Abstract][Full Text] [Related]
30. Computational Prediction and Validation of Tumor-Associated Neoantigens. Roudko V; Greenbaum B; Bhardwaj N Front Immunol; 2020; 11():27. PubMed ID: 32117226 [TBL] [Abstract][Full Text] [Related]
31. Induction of Neoantigen-Specific Cytotoxic T Cells and Construction of T-cell Receptor-Engineered T Cells for Ovarian Cancer. Matsuda T; Leisegang M; Park JH; Ren L; Kato T; Ikeda Y; Harada M; Kiyotani K; Lengyel E; Fleming GF; Nakamura Y Clin Cancer Res; 2018 Nov; 24(21):5357-5367. PubMed ID: 29720506 [No Abstract] [Full Text] [Related]
32. T Cell Receptors for Gene Transfer in Adoptive T Cell Therapy. Sharma P; Kranz DM Crit Rev Immunol; 2019; 39(2):105-122. PubMed ID: 31679251 [TBL] [Abstract][Full Text] [Related]
33. Pathogen-Boosted Adoptive Cell Transfer Therapy Induces Endogenous Antitumor Immunity through Antigen Spreading. Xin G; Khatun A; Topchyan P; Zander R; Volberding PJ; Chen Y; Shen J; Fu C; Jiang A; See WA; Cui W Cancer Immunol Res; 2020 Jan; 8(1):7-18. PubMed ID: 31719059 [TBL] [Abstract][Full Text] [Related]
34. Immunotherapeutic targeting of shared melanoma-associated antigens in a murine glioma model. Prins RM; Odesa SK; Liau LM Cancer Res; 2003 Dec; 63(23):8487-91. PubMed ID: 14679014 [TBL] [Abstract][Full Text] [Related]
35. Adoptive transfer of vaccine-induced peripheral blood mononuclear cells to patients with metastatic melanoma following lymphodepletion. Powell DJ; Dudley ME; Hogan KA; Wunderlich JR; Rosenberg SA J Immunol; 2006 Nov; 177(9):6527-39. PubMed ID: 17056585 [TBL] [Abstract][Full Text] [Related]
36. Anti-tumour effect of neo-antigen-reactive T cells induced by RNA mutanome vaccine in mouse lung cancer. Sun J; Zhang J; Hu H; Qin H; Liao X; Wang F; Zhang W; Yin Q; Su X; He Y; Li W; Wang K; Li Q J Cancer Res Clin Oncol; 2021 Nov; 147(11):3255-3268. PubMed ID: 34291357 [TBL] [Abstract][Full Text] [Related]
37. Defining the ability of cyclophosphamide preconditioning to enhance the antigen-specific CD8+ T-cell response to peptide vaccination: creation of a beneficial host microenvironment involving type I IFNs and myeloid cells. Salem ML; Kadima AN; El-Naggar SA; Rubinstein MP; Chen Y; Gillanders WE; Cole DJ J Immunother; 2007 Jan; 30(1):40-53. PubMed ID: 17198082 [TBL] [Abstract][Full Text] [Related]
38. High efficiency TCR gene transfer into primary human lymphocytes affords avid recognition of melanoma tumor antigen glycoprotein 100 and does not alter the recognition of autologous melanoma antigens. Morgan RA; Dudley ME; Yu YY; Zheng Z; Robbins PF; Theoret MR; Wunderlich JR; Hughes MS; Restifo NP; Rosenberg SA J Immunol; 2003 Sep; 171(6):3287-95. PubMed ID: 12960359 [TBL] [Abstract][Full Text] [Related]
39. Personalized T cell-mediated cancer immunotherapy: progress and challenges. Bethune MT; Joglekar AV Curr Opin Biotechnol; 2017 Dec; 48():142-152. PubMed ID: 28494274 [TBL] [Abstract][Full Text] [Related]
40. Recognition of human gastrointestinal cancer neoantigens by circulating PD-1+ lymphocytes. Gros A; Tran E; Parkhurst MR; Ilyas S; Pasetto A; Groh EM; Robbins PF; Yossef R; Garcia-Garijo A; Fajardo CA; Prickett TD; Jia L; Gartner JJ; Ray S; Ngo L; Wunderllich JR; Yang JC; Rosenberg SA J Clin Invest; 2019 Nov; 129(11):4992-5004. PubMed ID: 31609250 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]